Please use this identifier to cite or link to this item:
Title: Antidiabetic and antihyperlipidemic effects of Artemisia absinthium L., Citrullus colocynthis (L.) Schrad. and Gymnema sylvestre (Retz.) R.Br. ex Sm. on type II diabetes hyperlipidemic patients
Authors: Hassan, Mukhtiar
Niazi, Aneela Tariq
Khan, Samiullah
Gul, Farzana
Keywords: Clinical trials;Diabetes;Traditional medicine
Issue Date: Apr-2018
Publisher: NISCAIR-CSIR, India
IPC Code: Int. Cl.8: A61K 36/00, A01D 16/02,
Abstract: Artemisia absinthium L., Citrullus colocynthis (L.) Schrad. and Gymnema sylvestre (Retz.) R.Br. ex Sm. have been used in Asian countries for thousands of years to treat diabetes. This study was conducted to evaluate hypoglycemic and antihyperlipidemic effects in type II hyperlipidemic diabetic patients. Study is blind randomized placebo-controlled clinical trials over 40 days. Individuals were divided randomly into 4 groups 1, 2, 3 & 4. Ten individuals were in each group. Group 1 was allocated for G. sylvestre, 2 for A. absinthium, 3 for C. colocynthis and 4 for placebo. Medication (1.0 g/day) was administered for 40 days. From each individual of each group on day 0, 10, 20, 30 and 40 blood samples were collected in fasting condition. Serum glucose values in group 1 dropped most considerably (p < 0.05). Diabetic individuals of all 3 groups as compared to control and placebo group, showed significantly lowered fasting serum glucose level (p < 0.05). Fasting serum triglycerides, cholesterol, HDL-cholesterol and LDL-cholesterol of all 3 groups were not reduced significantly at (p < 0.05) as compared to control and placebo groups. So it may be suggested that a type II diabetic patient can safely be switched from costly conventional antidiabetic medicine to cheap natural products.
Page(s): 233-239
ISSN: 0975-1068 (Online); 0972-5938 (Print)
Appears in Collections:IJTK Vol.17(2) [April 2018]

Files in This Item:
File Description SizeFormat 
IJTK 17(2) 233-239.pdf116.81 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.